iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 2,500 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $87.88, for a total value of $219,700.00. Following the completion of the transaction, the chief executive officer owned 2,172,500 shares in the company, valued at approximately $190,919,300. The trade was a 0.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Up 3.5%

NASDAQ:IRMD traded up $3.04 on Wednesday, hitting $90.40. The stock had a trading volume of 169,288 shares, compared to its average volume of 90,268. The business’s fifty day moving average is $93.22 and its 200 day moving average is $94.91. The company has a market cap of $1.16 billion, a PE ratio of 49.40 and a beta of 0.90. iRadimed Corporation has a 52 week low of $50.88 and a 52 week high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.03. The business had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities analysts predict that iRadimed Corporation will post 1.52 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be issued a $0.20 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio is presently 43.72%.

Wall Street Analyst Weigh In

IRMD has been the subject of several analyst reports. Lake Street Capital reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Freedom Capital raised iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings raised iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 6th. Finally, Roth Mkm reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, iRadimed presently has a consensus rating of “Buy” and an average target price of $120.00.

Institutional Trading of iRadimed

Institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC raised its stake in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares during the last quarter. CWM LLC raised its stake in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the last quarter. Quarry LP purchased a new stake in shares of iRadimed in the third quarter worth approximately $40,000. State of Alaska Department of Revenue purchased a new stake in shares of iRadimed during the third quarter valued at approximately $47,000. Finally, Tower Research Capital LLC TRC increased its position in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.